Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of multiple malignant tumors. To date, toripalimab has been approved for marketing ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, “Toripalimab has made significant strides in its internationalization. As of today, toripalimab has been approved in 35 countries ...

The company said it would transfer a low, double-digit percentage of proceeds it receives from toripalimab net sales in ...

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) said that it has launched Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma.

The two treatments to be most recently rejected were Hutchmed’s surufatinib, and Coherus BioSciences and Shanghai Junshi Biosciences’ toripalimab. Coherus’ treatment was rejected on grounds ...

In addition to the foreign antivirals, some pet owners also have opted for similar but cheaper Covid medicines developed by homegrown companies including Henan Genuine Biotech, Simcere Pharmaceutical ...

Simcere Pharmaceutical Group and Shanghai Junshi Biosciences. Merck did not immediately reply to Bloomberg’s e-mailed request for comments. Chinese pet owner’s use of human Covid-19 drugs on ...